DE69840342D1 - Steuerbare phosphofructokinase und der warburg effekt - Google Patents

Steuerbare phosphofructokinase und der warburg effekt

Info

Publication number
DE69840342D1
DE69840342D1 DE69840342T DE69840342T DE69840342D1 DE 69840342 D1 DE69840342 D1 DE 69840342D1 DE 69840342 T DE69840342 T DE 69840342T DE 69840342 T DE69840342 T DE 69840342T DE 69840342 D1 DE69840342 D1 DE 69840342D1
Authority
DE
Germany
Prior art keywords
ipfk
phosphofructokinase
controllable
warburg effect
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840342T
Other languages
English (en)
Inventor
Richard J Bucala
Jason A Chesney
Robert A Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Cytokine Pharmasciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokine Pharmasciences Inc filed Critical Cytokine Pharmasciences Inc
Application granted granted Critical
Publication of DE69840342D1 publication Critical patent/DE69840342D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01105—6-Phosphofructo-2-kinase (2.7.1.105)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
DE69840342T 1997-10-31 1998-10-30 Steuerbare phosphofructokinase und der warburg effekt Expired - Lifetime DE69840342D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/961,578 US6413939B1 (en) 1997-10-31 1997-10-31 Inducible phosphofructokinase and the Warburg effect
PCT/US1998/023155 WO1999023108A1 (en) 1997-10-31 1998-10-30 Inducible phosphofructokinase and the warburg effect

Publications (1)

Publication Number Publication Date
DE69840342D1 true DE69840342D1 (de) 2009-01-22

Family

ID=25504669

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840342T Expired - Lifetime DE69840342D1 (de) 1997-10-31 1998-10-30 Steuerbare phosphofructokinase und der warburg effekt

Country Status (10)

Country Link
US (4) US6413939B1 (de)
EP (1) EP1042350B1 (de)
JP (1) JP4369044B2 (de)
AT (1) ATE417054T1 (de)
AU (1) AU1370799A (de)
CA (1) CA2308091A1 (de)
DE (1) DE69840342D1 (de)
ES (1) ES2319345T3 (de)
IL (1) IL135887A0 (de)
WO (1) WO1999023108A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413939B1 (en) 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect
MY140679A (en) * 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
GB0216097D0 (en) * 2002-07-11 2002-08-21 Univ London Treatment of proliferative disorders
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
MXJL06000006A (es) * 2003-08-22 2006-05-04 Avanir Pharmaceuticals Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre.
WO2006065967A2 (en) * 2004-12-15 2006-06-22 General Atomics Allosteric enzyme coupled immunoassay (aecia)
CA2600175A1 (en) * 2005-03-24 2006-03-20 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
US8662667B2 (en) * 2007-12-21 2014-03-04 Carl Zeiss Meditec Ag Ophthalmologic visualization system
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
US9012242B2 (en) * 2010-09-20 2015-04-21 Caliper Life Sciences Multivalent fluorescent probes
EP2532747B1 (de) * 2011-06-09 2015-12-02 Deutsches Krebsforschungszentrum Modulatoren von Glycerin-3-phosphatdehydrogenase (GPD2) zur Therapie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472516B1 (en) * 1995-10-24 2002-10-29 The Garvan Institute Of Medical Research Progestin-regulated gene
US6413939B1 (en) 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect

Also Published As

Publication number Publication date
ES2319345T3 (es) 2009-05-06
US6596851B1 (en) 2003-07-22
IL135887A0 (en) 2001-05-20
AU1370799A (en) 1999-05-24
ATE417054T1 (de) 2008-12-15
EP1042350A4 (de) 2003-01-02
JP2001521731A (ja) 2001-11-13
US6255046B1 (en) 2001-07-03
CA2308091A1 (en) 1999-05-14
US6413939B1 (en) 2002-07-02
EP1042350B1 (de) 2008-12-10
EP1042350A1 (de) 2000-10-11
WO1999023108A9 (en) 1999-08-19
WO1999023108A1 (en) 1999-05-14
US20030228568A1 (en) 2003-12-11
JP4369044B2 (ja) 2009-11-18

Similar Documents

Publication Publication Date Title
ATE417054T1 (de) Steuerbare phosphofructokinase und der warburg effekt
Arora et al. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
Millard et al. Determination of the DNA crosslinking sequence specificity of reductively activated mitomycin C at single-nucleotide resolution: deoxyguanosine residues at CpG are crosslinked preferentially
ES2144391T3 (es) Derivados de alcoxi-4(1h)-piridona, sus procedimientos de preparacion y su utilizacion como medicamentos.
DE69333073D1 (de) Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen
RU93051543A (ru) Производные акридина, способ получения, фармацевтическая композиция и способ лечения злокачественных опухолей
BG103965A (en) QUINOLINE AND QUINOXALINE COMPOUNDS INHIBITING THE RECEIVED FROIM THROMBOCYTES FACTOR OF GROWTH AND/OR P561ck THYROSINEKINASES
ES2118593T3 (es) Analogos de nucleotidos de pteridina como sondas fluorescentes de adn.
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
EA199900349A1 (ru) Каталитическая субъединица теломеразы человека
Ovejera et al. Efficacy of 6-Diazo-5-oxo-l-norleucine and N-[N-γ-Glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice
WO2000047215A3 (en) Methods for anti-tumor therapy
BR0008788A (pt) Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
WO2001085219A3 (en) Identification, diagnosis, and treatment of breast cancer
ES2114615T3 (es) Nueva sonda para el diagnostico de tumores o la terapia de tumores.
ATE200427T1 (de) Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
HUP0300007A2 (en) Antibody with specificity for colon cancer
Li et al. Plant sterols as selective DNA polymerase β lyase inhibitors and potentiators of bleomycin cytotoxicity
ATE295367T1 (de) Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält
ES2154290T3 (es) Estimulacion de la diferenciacion celular por sindecano.
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
DE69814691D1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
FR2654106B1 (fr) Derives phosphores de cytosine, leur preparation et leur application en therapeutique.
ATE218372T1 (de) Antisense oligonnukleotide die mit der mrna cap aktivität interferieren und die translation inhibieren
Riva et al. Effect of tetrahydrouridine on metabolism and transport of 1-β-D-arabinofuranosylcytosine in human cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1042350

Country of ref document: EP

Representative=s name: HAFNER & PARTNER, DE

R081 Change of applicant/patentee

Ref document number: 1042350

Country of ref document: EP

Owner name: FERRING B.V., NL

Free format text: FORMER OWNER: CYTOKINE PHARMASCIENCES, INC., KING OF PRUSSIA, US

Effective date: 20121113

R082 Change of representative

Ref document number: 1042350

Country of ref document: EP

Representative=s name: HAFNER & PARTNER, DE

Effective date: 20121113